Indivior plc (lon:indv)
Indivior – Correctly Priced Or Oversold?

Indivior plc Financials

ItemCurrent PeriodPrevious Period
YearN/A N/A
Adjusted Earnings
Adjusted EBITDA
Statutory Profit
Adjusted Profit
Total Debt
Net Debt

Commentary History
No ticker supplied in the url so commentary history can not be collected.
Indivior plc Share Price
Grade:No grade has been assigned to this company
Title: Indivior – Correctly Priced Or Oversold?
Company: INDV - Indivior plc
Share Price Then: 31p
Author: Ian Smith
Date: Sun 14 Apr 2019
Comments: Indivior are mostly a supplier of a single product Suboxone (buprenorphine and naloxone) Film a drug used to treat people with opiate addiction and which accounts for about 80% of their revenue.

Its share price has been tumbling for a while now and there are two very clear reasons for this.

Suboxone was granted an Orphan Drug approval (a drug for a condition with a small number of sufferers) in the USA 2002 meaning that no rival drug would be approved for 7 years after which generic and cheaper versions would be allowed.

The first and longer term reason is that they have a patent in the USA for Suboxone Film which is a Suboxone supplied as a small patch that is placed in the mouth rather than as a tablet. The patent for this patch is being challenged and if the challenge succeeds a product that is pretty much a cash cow could be wiped out.

The drug iteself is not Indivior's advantage, it is the "little bit of 'plastic'" soaked in the drugs. Its big selling point is that film is safer than tablets and as the film was patented it gave Invidior an advantage over tablet providers.

The second problem announced a few days ago is that Invidior have been charged in the USA as being part of a longer term problem that covers the whole medical industry.

Basically the general allegations are that since 2002 pharmaceutical companies started selling opioid based pain medication and promised that the recipients would not become addicted and misuse them, but a lot have. Added to this there are questions about incentives being offered to doctors to prescribe certain products.

More specifically The government makes two main claims against the company: that it aided the careless and clinically unwarranted prescribing by doctors of SUBOXONE® products to too many people or in too high doses; and that it misled doctors and patients by claiming that SUBOXONE® film was safer than tablets at reducing accidental exposure to children.

As an outsider it is impossible to predict the future of the US legal action and intially I was considering the possibility that the legal action may be in part about being seen to do something.

Then I read the suit and in 2014 Medicare spent $147,704,000 and Medicaid $386,685,000 on Suboxone film, how will a jury see that regardless of the facts?

The charges are complicated further as Reckitt spun off Indivior as a separate company in Dec 2014 but started selling Suboxone in the USA in 2002 .So even if there are actions that someone is liable for the question is it is RB Group or Indivior?

It appears to me that if the prosecution succeeds substantially then Indivior will be wiped out without actually paying the fine, so why not alter the suit and go after RB Group which could survive a fine of a $2.3billion?

Added to this risk is the predicted massive drop in sales which leads me to consider that Indivior could be a great day trading share until the price settles but not something to buy today for a long term hold expecting a 100% share price rise in a year or two.
Read Count: 214/7051

Buy/No Buy In A Nutshell
Initial Review Price0p
Last Review Price0p
Last Review Date
Navigation & Details

Share Commentaries, their purpose.